Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor in Patients With Advanced Solid Tumor
Clinical trial NCT04648254 · COMPLETED
Trial details
- NCT number
- NCT04648254
- Sponsor
- Qurient Co., Ltd.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2020-11-18
- Primary completion
- 2025-12-23
- Enrollment
- 51
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.